Patents by Inventor Reshma Singh

Reshma Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY
    Publication number: 20230000964
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 5, 2023
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
    Patent number: 11413340
    Abstract: Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: August 16, 2022
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania, Dana-Farber Cancer Institute, Inc., President and Fellows of Harvard College
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • TREATMENT OF CANCER USING HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20220064316
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Application
    Filed: June 25, 2021
    Publication date: March 3, 2022
    Inventors: Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Jonathan Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
  • Anti-BCMA chimeric antigen receptor
    Patent number: 11084880
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: August 10, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Jonathan Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
  • TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210139595
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Application
    Filed: October 28, 2020
    Publication date: May 13, 2021
    Inventors: Hilmar Erhard Ebersbach, Thomas Huber, Julia Jascur, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
  • Treatment of cancer using a CD33 chimeric antigen receptor
    Patent number: 10851166
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: December 1, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hilmar Erhard Ebersbach, Thomas Huber, Julia Jascur, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
  • TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20200215171
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Application
    Filed: December 27, 2019
    Publication date: July 9, 2020
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Jonathan Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Treatment of cancer using a CLL-1 chimeric antigen receptor
    Patent number: 10568947
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: February 25, 2020
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, Saar Gill, David Glass, Julia Jascur, Saad Kenderian, Joan Mannick, Michael C. Milone, Leon Murphy, Celeste Richardson, Reshma Singh, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • System and apparatus for and methods of control of localized energy use in a building using price set points
    Patent number: 10496066
    Abstract: This disclosure provides systems, methods, and apparatus related to energy management in a building. In one aspect, a method includes providing a plurality of apparatus. Each apparatus of the plurality of apparatus includes a controller, a light, and a heating/cooling device. The controller is in communication with a control system, and the control system controls the electrical system of a building. A power price is received from the control system at a first apparatus of the plurality of apparatus. The power price is compared to a set point power price. Power supplied to at least one of the light of the first apparatus, the heating/cooling device of the first apparatus, a lighting device in a region proximate the first apparatus, and a heating/cooling device in the region proximate the first apparatus is adjusted based on comparing the power price to the set point power price.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: December 3, 2019
    Assignee: The Regents of the University of California
    Inventors: Vishal Garg, Niranjan Reddy, Sam Babu Godithi, Richard E. Brown, Christian Kohler, Reshma Singh
  • TREATMENT OF CANCER USING 5 HUMANIZED ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20190153061
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Application
    Filed: November 21, 2018
    Publication date: May 23, 2019
    Inventors: Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Jonathan Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
  • Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
    Patent number: 10174095
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: January 8, 2019
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
  • MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY
    Publication number: 20190000944
    Abstract: Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
    Type: Application
    Filed: December 21, 2016
    Publication date: January 3, 2019
    Inventors: Jennifer Brogdon, Hwai Wen Chang, Boris Engels, Gordon James Freeman, Gerhard Johann Frey, Jennifer Marie Mataraza, Reshma Singh, Arlene Helen Sharpe
  • Listeria-based adjuvants
    Patent number: 10064898
    Abstract: This invention provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: September 4, 2018
    Assignees: ADVAXIS, INC., UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: John Rothman, Anu Wallecha, Reshma Singh, Donald A. Harn, Jr., Yvonne Paterson
  • Suppressor cell function inhibition following vaccine treatment
    Patent number: 10058599
    Abstract: This invention provides methods and compositions for using a live attenuated Listeria for inhibiting cell-mediated suppression of anti-disease infiltrating T lymphocytes in a subject having the disease.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: August 28, 2018
    Assignee: ADVAXIS, INC.
    Inventors: Reshma Singh, Anu Wallecha
  • Combination Therapies With Recombinant Listeria Strains
    Publication number: 20180153974
    Abstract: The disclosure is directed to compositions comprising an oncolytic virus, chimeric antigen receptor T cells (CAR T cells), a therapeutic or immunomodulating monoclonal antibody, a targeting thymidine kinase inhibitor (TKI), or an adoptively transferred cells incorporating engineered T cell receptors, and a live attenuated recombinant Listeria strain comprising a fusion protein of a Truncated LLO, a truncated ActA or a PEST-sequence peptide fused to a tumor-associated antigen. The disclosure is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering the same, with or without an additional radiation therapy treatment.
    Type: Application
    Filed: December 18, 2015
    Publication date: June 7, 2018
    Inventors: Robert Petit, Anu Wallecha, Yvonne Patterson, Reshma Singh
  • SYSTEM AND APPARATUS FOR AND METHODS OF CONTROL OF ENERGY USE IN A BUILDING
    Publication number: 20180059633
    Abstract: This disclosure provides systems, methods, and apparatus related to energy management in a building. In one aspect, a method includes providing a plurality of apparatus. Each apparatus of the plurality of apparatus includes a controller, a light, and a heating/cooling device. The controller is in communication with a control system, and the control system controls the electrical system of a building. A power price is received from the control system at a first apparatus of the plurality of apparatus. The power price is compared to a set point power price. Power supplied to at least one of the light of the first apparatus, the heating/cooling device of the first apparatus, a lighting device in a region proximate the first apparatus, and a heating/cooling device in the region proximate the first apparatus is adjusted based on comparing the power price to the set point power price.
    Type: Application
    Filed: August 18, 2017
    Publication date: March 1, 2018
    Inventors: Vishal Garg, Niranjan Reddy, Sam Babu Godithi, Richard E. Brown, Christian Kohler, Reshma Singh
  • TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20180044423
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Application
    Filed: August 29, 2017
    Publication date: February 15, 2018
    Inventors: Hilmar Erhard Ebersbach, Thomas Huber, Julia Jascur, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
  • Treatment of cancer using a CD33 chimeric antigen receptor
    Patent number: 9777061
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: October 3, 2017
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hilmar Erhard Ebersbach, Thomas Huber, Julia Jascur, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
  • LISTERIA-BASED ADJUVANTS
    Publication number: 20160324903
    Abstract: This invention provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject.
    Type: Application
    Filed: July 27, 2016
    Publication date: November 10, 2016
    Applicants: ADVAXIS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: John ROTHMAN, Anu WALLECHA, Reshma SINGH, Donald A. HARN, JR., Yvonne PATERSON
  • Listeria-based adjuvants
    Patent number: 9463227
    Abstract: This invention provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: October 11, 2016
    Assignees: ADVAXIS, INC., THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: John Rothman, Anu Wallecha, Reshma Singh, Donald A. Harn, Jr., Yvonne Paterson